Skip to main content
SMFM 2026 Pregnancy Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Additional registration fee required
Additional registration fee required
Faculty have requested this content not be shared outside of the session
Faculty have requested this content not be shared outside of the session
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Recording available 2/16-5/2
Recording available 2/16-5/2
AIUM Credit
AIUM Credit
Foundation Awardee
Foundation Awardee
Poster Icons
Abstract Award
Abstract Award
Foundation Awardee
Foundation Awardee

Oral Concurrent Session 9 - Quality

Oral Concurrent Sessions

Oral Concurrent Session 9 - Quality

(97) Maternal Outcomes After Implementation of a State Medicaid Agency and Hospital System Partnership Care Model

Friday, February 13, 2026
9:45 AM - 10:00 AM  
Location: Summit 218 - 221
Abstract Award
Objective:

Substance Use Disorder (SUD) is one of the leading causes of maternal morbidity and mortality throughout the United States.  We implemented a Maternal Opioid Misuse Model (MOM) pilot program via a partnership between a safety net hospital system and Texas Medicaid agency designed to optimize maternal outcomes related to SUD.


Study Design:

The Center for Medicaid Service funded the MOM program from 2020-2025.  The program goals included improving quality of care, reducing cost and increasing access to treatment services.  Model design key features (figure 1) include: universal screening and referral, integrated medical, behavioral health and community services, targeted doula and navigation support, individualized pain management strategies, “Care by Parent Suites” for an Eat Sleep Console program and implementation of a Plan of Safe Care.   Demographics and outcome data were collected for women with OUD in MOM and compared to similar populations in other studies, MMRC data, and hospital level data.



Results:

135 pregnancies were enrolled in the program from 2022-2025 who reported high rates of physical, emotional or sexual abuse (74%) and health related social needs (78%).  The majority were on MOUD (85%), including methadone (36%) and Buprenorphine (65%). Outcome data are included in table 1. Universal screening for SUD increased, and 2% of hospital patients screened positive for being at risk for complications related to SUD.  Maternal-infant dyad separation decreased from 68% to 15%. Diagnosis of neonatal opioid withdrawal syndrome (NOWS) decreased from 58% to 14. The NICU length of stay decreased from a historic average of 16 to 19 days to 4 days. 



Conclusion:

Integrated care models between health care systems and state Medicaid agencies have the potential to improve outcomes for pregnant patients with opioid use disorder.